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Objective: To determine the effect of changing anticholinergic therapy in patients with COPD 
from ipratropium to tiotropium on pulmonary function.
Methods: We examined records of patients prescribed high-dose ipratropium, who were 
subsequently converted to tiotropium. Spirometric values were obtained within 2 days of the 
change in medication and after 56 to 224 days of the switch to tiotropium.
Results: 15 subjects were documented to have filled a prescription for ipratropium-containing 
medications the month prior to the change. Medication compliance over the 6 months prior to the 
switch in these patients was 72% ± 31% (mean ± SD) for ipratropium compared to 87% ± 14% for 
tiotropium over the 6-month period after the switch (P = 0.1). FEV1 improved from 1.12 ± 0.39 L 
at baseline to 1.37 ± 0.49 L after the change to tiotropium (P = 0.01). FVC also improved from 
2.45 ± 0.73 L at baseline to 2.72 ± 0.69 L after the change (P = 0.04). Maximal voluntary 
ventilation was also increased from 39.67 ± 10.7 L/min to 45.13 ± 15.8 L/min (P = 0.045).
Conclusions: We conclude that replacing high-dose ipratropium with tiotropium therapy 
significantly improves pulmonary function in a clinical setting.
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Introduction
To date only smoking cessation or long-term oxygen therapy in patients with chronic 
obstructive pulmonary disease (COPD) and resting hypoxemia have been shown to 
impact mortality in this disorder.1,2 However, some pharmacologic therapies impact a 
number of clinical parameters in patients with COPD.2,3 Currently there are 2 available 
inhaled anticholinergic medications, ipratropium and tiotropium, which improve air 
flow in patients with COPD. Tiotropium has a prolonged duration of action (24 hours) 
compared to ipratropium.3 A recent study has suggested tiotropium is cost-effective 
compared to ipratropium.4 Tiotropium has been shown to improve 1) forced expiratory 
volume in 1 second (FEV1),3 2) quality of life, and 3) exercise capacity and dyspnea 
compared to subjects treated with placebo or ipratropium.5 Although these premarketing 
studies suggested an advantage of tiotropium over ipratropium in treatment of COPD 
patients there has not been any report of the effects of changing from ipratropium to 
tiotropium therapy in COPD patients followed in a general clinical setting.
Methods
selection of subjects
Clinical records were reviewed of patients followed in a specialized clinic for COPD 
at the Birmingham VAMC who were previously treated with a regimen that contained International Journal of COPD 2009:4 392
Gauhar et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
high-dose ipratropium. This included use of the combination 
metered dose inhaler containing ipratropium (21 µg per puff), 
and albuterol (120 µg per puff), 2 puffs 4 times a day followed 
by ipratropium metered dose inhaler (MDI) (18 µg per puff) 
4 inhalations 4 times a day. This resulted in a total of 456 µg 
of ipratropium inhaled each day. Patients were subsequently 
changed to tiotropium 18 µg capsule inhaled daily with 
albuterol MDI when necessary. Records of 24 subjects who 
had spirometry performed on the day of the change from 
ipratropium to tiotropium were further examined. Four of 
these subjects had evidence of a COPD exacerbation on the 
day of the switch and were not evaluated leaving 20 subjects 
for further evaluation. When only subjects were included 
who had refilled the prescription for ipratropium containing 
medications in the month prior to the switch, to minimize 
noncompliance as a complicating issue, a total of 15 remained 
for final evaluation.
Calculation of medication compliance
The records of prescription refills were examined for each 
of the 15 subjects and the number of prescription refills of 
ipratropium over the 6 months prior to, or tiotropium over the 
6 months after the switch were determined. The percentage 
of compliance with the respective medication was calculated 
by the number of months the medication was refilled in 
those 6 months. If the subject refilled the medication 6 times 
(all prescriptions were 1 month supply at a time) compliance 
was calculated as 100%.
Pulmonary function testing
Spirometry was performed by American Thoracic Society 
guidelines.6
statistical analysis
Differences between means were determined by T test. 
A P value less then 0.05 was considered significant.
Results
subjects and medication compliance
Table 1 shows demographics of the 15 subjects in the study. 
Of the total number of subjects 15 patients had stage III, 
2 subjects had stage IV and 4 subjects had stage II COPD 
as defined by GOLD.7 All but 1 of the subjects had quit 
smoking. The average age for the 14 males and 1 female 
was 69.53 years. Compliance for anticholinergic use was 
72% ± 31% (mean ± SD) for ipratropium 6 months prior 
to the switch compared to 87% ± 14% for tiotropium over 
the 6 month period after change in medication (P = 0.1). All 
patients were using the combination salmeterol/fluticasone 
inhaler Advair® during the month prior to the anticholinergic 
switch and through the entire period of the study.
Pulmonary function testing
Figure 1 shows individual data for the FEV1 (A) and FVC 
(B) determined in the 15 subjects at baseline and after the 
change to tiotropium. FEV1 increased by an average of 
155 mL (12.8%) (P = 0.01). Five of the 15 subjects showed 
Table 1 Characteristics of subjects at baseline
Subject no. Age  Gender Smoking status FEV1 (%pred) FVC (%pred) Comorbidities
1 73 M Former 1.11 (35) 2 (46) PUD, GeRD, hL
2 81 M Former 1.41 (50) 1.72 (40) PUD,   A Fib, CAD
3 67 M Former 0.49 (14) 1.4 (30) UC, Psoriasis, DM, GeRD
4 71 M Former 1.00 (36) 2.28 (60) BPh, OsA, CAD
5 76 M Former 0.87 (30) 2.43 (60) CAD, Cataracts
6 67 M Former 0.84 (27) 1.53 (36) hTn, hL
7 59 M Former 1.14 (32) 2.43 (52) hTn, OP, OsA, hT, hL
8 60 F Current 1.40 (56) 1.74 (58) Depression, DM, hTn, hL
9 73 M Former 1.78 (54) 4.06 (88) DVT, OP, hL, AsCVD
10 77 M Former 0.98 (32) 2.3 (53) GeRD, hTn, Bladder Ca
11 78 M Former 1.27 (44) 3.16 (77) hTn
12 64 M Former 2.07 (64) 3.1 (71) CAD, hL, GeRD, Psoriasis
13 70 M Current 1.53 (49) 2.54 (59) OP, hTn, GeRD, CAD
14 63 M Former 1.03 (31) 2.9 (65) hTn, BPh, hL
15 64 M Former 1.26 (39) 3.16 (73) DM, hTn, hL, GeRD
Abbreviations:   A fib, atrial fibrillation;   ASCVD, atherosclerotic cardiovascular disease; BPH, benign prostatic hypertrophy; CAD, coronary artery disease;  DM, diabetes mellitus; 
DVT, deep vein thrombosis; GERD, gastroesophageal reflux disease; HL, hyperlipidemia; HT, hyperthyroidism; HTN, hypertension; OP, osteoporosis; OSA, obstructive sleep 
apnea; PUD, peptic ulcer disease; UC, ulcerative colitis.International Journal of COPD 2009:4 393
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an improvement of over 200 mL in FEV1. FVC also improved 
by an average of 273 mL (11.1%) P = 0.04. Maximal volun-
tary ventilation improved 5.46 L/min, an average of 13.8% 
(P = 0.045) (data not shown).
Discussion
Our study suggests replacing high-dose inhaled ipratropium 
with tiotropium significantly improves FVC and FEV1. 
The effect on FEV1 suggests tiotropium has an advantage 
in improving airflow compared to high-dose ipratropium 
while effects of the change on FVC may be due to lessened 
air trapping.
A number of premarketing studies suggested tiotropium 
provides better bronchodilation compared to ipratropium 
administered 4 times a day and salmetrol administered 
twice a day, as evidenced by peak FEV1, trough FEV1 
and area under the curve.3 However, in all of these studies 
the comparator group was treated with a lower dose of 
ipratropium then was employed in the current study. 
Ikeda et al demonstrated that increasing doses of ipratropium 
up to 240 µg had progressively beneficial effects on exercise 
capacity and FEV1.8 The dose of ipratropium used in our 
study at each single treatment time was 114 µg, less than 
the optimal dose demonstrated in that study but more 
than comparator ipratropium arms in premarket studies of 
tiotropium. However, in clinical practice use of a higher dose 
of ipratropium to achieve a dose of 160 µg at each dosing 
time would be problematic because of the large number of 
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Figure 1 effects of the switch from ipratropium anticholinergic therapy to tiotropium on FeV1 (A) and FVC (B).
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inhalations required per day and the cost of the number of 
inhalers required for that dose. To date, several more studies 
have demonstrated superior improvements in FEV1, FVC 
and FEV6 with tiotropium compared to placebo, ipratropium 
and long-acting β2-agonists.9–13 Tiotropium was shown to 
improve FEV1 regardless of the presence or absence of 
short-term improvement in FEV1.14 Moreover, improvements 
in inspiratory capacity and FEV1 with tiotropium in 
patients with hyperinflation are unrelated to small airway 
heterogeneity.15 Tiotropium has also been shown to reduce 
dynamic hyperinflation resulting in improved exercise 
endurance.3,16,17
Tiotropium has an excellent safety profile with dry 
mouth and urinary retention being the only major adverse 
events.3,13,18–20 The incidence of dry mouth was slightly greater 
than that seen with ipratropium.3 However, the effect was 
mild and did not lead to cessation of therapy. Serious adverse 
events occurred with the same frequency as in the control 
group.3 A recently published meta-analysis of 17 randomized 
controlled trials raised concerns about an increased risk 
of cardiovascular death, myocardial infarction and stroke 
among COPD patients with use of inhaled anticholinergics 
(ipratropium or tiotropium).21 However, the UPLIFT study 
did not demonstrate any such risks with long-term use of 
tiotropium.22
Treatment with tiotropium is cost-effective compared to 
ipratropium.4,23 In a retrospective pooled analysis of long-
acting bronchodilators, treatment with tiotropium was shown 
to save US$391 per year while gaining 13 quality-adjusted 
days compared with ipratropium.23 Since hospitalizations due 
to COPD exacerbations account for up to 70% of the medical 
care costs for COPD patients, reduction in hospitalizations 
is a major reason for cost-effectiveness of treatment with 
tiotropium.24,25
Our study suggests that tiotropium 18 µg in a once-daily 
regimen improves airway flow rates when compared to a 
previous regimen of 456 µg of ipratropium per day. This, 
and previous studies, suggest an advantage of long-acting 
anticholinergic agent over short-acting ipratropium. 
Larger studies may be needed to determine the “real 
world” physiologic and economic effect of changing from 
ipratropium to tiotropum as anticholinergic therapy.
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